Eagle Pharmaceuticals: Q3 Earnings Insights

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 350.00% over the past year to $1.17, which beat the estimate of $0.28.

Revenue of $49,928,000 rose by 21.34% from the same period last year, which beat the estimate of $47,020,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 02, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2F&eventid=2623150&sessionid=1&key=12B4C68175B19655E44747298480FB92&regTag=&sourcepage=register

Technicals

Company's 52-week high was at $64.94

52-week low: $33.80

Price action over last quarter: Up 7.88%

Company Overview

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.